e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

85.94 +0.92 (+1.08%)

Streaming Delayed Price Updated: 3:05 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady

Today 1:38 EDT

Blood products company Haemonetics (NYSE:HAE) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 million. Its no...

Via StockStory

Topics World Trade

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

August 06, 2026

Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339....

Via StockStory

What To Expect From Haemonetics’s (HAE) Q2 Earnings

August 04, 2026

Blood products company Haemonetics (NYSE:HAE) will be reporting results this Thursday before market open. Here’s what to look for. Haemonetics beat analysts’...

Via StockStory

1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm

July 28, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

Haemonetics (NYSE:HAE) Passes the Caviar Cruise Quality Test ↗

May 05, 2026

Via Chartmill

3 Healthcare Stocks with Questionable Fundamentals

July 23, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Via StockStory

1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm

July 15, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

3 Reasons HAE is Risky and 1 Stock to Buy Instead

June 30, 2026

Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This m...

Via StockStory

Topics Stocks Supply Chain

3 Profitable Stocks We Find Risky

June 26, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Haemonetics (HAE) Stock Is Up, What You Need To Know

May 22, 2026

What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the ...

Via StockStory

Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)

May 20, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

Via StockStory

3 Russell 2000 Stocks That Concern Us

May 18, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

3 Small-Cap Stocks We’re Skeptical Of

May 15, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Haemonetics Q4 Earnings Call Highlights ↗

May 10, 2026

Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies...

Via MarketBeat

Topics Earnings

Haemonetics (HAE) Q4 2026 Earnings Transcript ↗

May 08, 2026

Haemonetics (HAE) Q4 2026 Earnings Transcript

Via The Motley Fool

Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026

May 07, 2026

Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.8% year on year to $346.4 m...

Via StockStory

Haemonetics Earnings: What To Look For From HAE

May 05, 2026

Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results this Thursday before market hours. Here’s what to expect. Haemonetics beat...

Via StockStory

Topics Artificial Intelligence

1 Value Stock on Our Buy List and 2 Facing Headwinds

April 06, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Topics ETFs

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗

March 20, 2026

This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.

Via The Motley Fool

Topics Regulatory Compliance

2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges

March 13, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...

Via StockStory

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack

March 05, 2026

Via StockStory

3 Reasons HAE is Risky and 1 Stock to Buy Instead

March 03, 2026

Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65.64 per share. This was partly d...

Via StockStory

Topics Stocks Supply Chain

3 Profitable Stocks with Open Questions

March 01, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call

February 12, 2026

Haemonetics’ fourth quarter results were met with a negative market reaction, reflecting investor caution despite the company’s performance exceeding Wall Street’s revenue and earnings expectations....

Via StockStory

Topics Earnings

HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results

February 06, 2026

Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%...

Via StockStory

Haemonetics HAE Q3 2026 Earnings Call Transcript ↗

February 05, 2026

Haemonetics HAE Q3 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars

February 05, 2026

Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%...

Via StockStory

What To Expect From Haemonetics’s (HAE) Q4 Earnings

February 03, 2026

Blood products company Haemonetics (NYSE:HAE). will be reporting earnings this Thursday before market open. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: Haemonetics (NYSE:HAE)

January 28, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty stocks, including Haemonetics (NYSE:HAE) and its peers.

Via StockStory

The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market

January 23, 2026

As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy